ISRCTN52616678
Completed
未知
Pilot study to investigate the early prediction of toxicity following induction chemotherapy in Ewing's sarcoma by blood-borne biomarkers and correlation with age-dependent pharmacokinetic variation
The Newcastle Upon Tyne Hospitals NHS Foundation Trust (UK)0 sites139 target enrollmentFebruary 25, 2014
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Ewing's sarcoma
- Sponsor
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust (UK)
- Enrollment
- 139
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age 0 \- 24 years
- •2\. Diagnosis of histologically confirmed Ewing sarcoma
- •3\. Receiving VIDE or VDC/IE as part of standard clinical treatment
- •4\. Single or double lumen central venous catheter in place
- •5\. Written informed consent
- •6\. Protocol approval by national and local ethics committee, regulatory authority and Trust R\&D Departments
Exclusion Criteria
- •1\. Receiving nonstandard dose chemotherapy.
- •2\. Glomerular filtration rate \<60 ml/min/1\.73m2\.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Study to investigate the early prediction of toxicity following chemotherapy and differences in drug handling in Ewing's sarcoma patientsEwing sarcoma patientsMedDRA version: 17.0Level: PTClassification code 10015560Term: Ewing's sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-000052-17-GBThe Newcastle Upon Tyne Hospitals NHS Foundation Trust
Not yet recruiting
Not Applicable
The effect of graduated return to high-intensity exercise on time to return to play in the context of sports-related concussions.Sports-related concussionMild Traumatic Brain InjuryACTRN12618000485235Dr Hamish Osborne50
Completed
Phase 1
CytoMegaloVirus: Alternate donor Study of Pre-Emptive Cellular TherapyISRCTN75391842Cell Medica Ltd (UK)18
Active, not recruiting
Phase 1
A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplastic syndromes after allogeneic stem cell transplantatiorelapsing acute leukemia, relapsing myelodysplastic syndromesMedDRA version: 17.0Level: LLTClassification code 10000835Term: Acute leukemiaSystem Organ Class: 100000004864MedDRA version: 17.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2013-005446-11-DEGoethe-University Frankfurt40
Recruiting
Not Applicable
A randomized pilot study to search the predictive parameters of PSK responder in patients with colorectal cancercolorectal cancerJPRN-UMIN000010046Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine210